Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
FLUCONAZOLE
Baxter Healthcare Limited
2 Mg/Ml
Solution for Infusion
2007-09-07
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fluconazole Redibag 2 mg/ml Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of Solution for Infusion contains 2 mg of Fluconazole. 50 ml Solution for Infusion contains 100 mg Fluconazole 100 ml Solution for Infusion contains 200 mg Fluconazole 200 ml Solution for Infusion contains 400 mg Fluconazole Excipients: 1 ml contains 9 mg of sodium chloride. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion. Clear, colourless solution and essentially free from particles. The solution is iso-osmotic. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Adults Treatment of mycoses caused by _Candida_, _Cryptococci _and other susceptible yeasts, in particular: Systemic candidiasis (including disseminated deep infections and peritonitis) Severe mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis and non-invasive bronchopulmonary candidiasis), where oral treatment is not possible. Cryptococcal meningitis in adults Prophylaxis against deep _Candida _infections (especially _Candida albicans_) in patients with neutropenia due to bone marrow transplantation. Consideration should be given to official guidance on the appropriate use of antifungal agents. Before initiating treatment samples should be taken for microbiological analysis and the suitability of the therapy should subsequently be confirmed (see sections 4.2 Posology and method of administration and 5.1 Pharmacodynamic properties). In some patients with severe cryptococcal meningitis the mycological response during fluconazole treatment may be slower compared to other treatments (see section 4.4). Children and adolescents Treatment of mycoses caused by _Candida _and other susceptible yeasts, in particular: Lire le document complet